Sources of Support: None. Conflicts of Interest: Shumei Kato serves as a consultant for Foundation Medicine and receives speaker's fees from Roche. Razelle Kurzrock has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, and Konica Minolta, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Roche, and NeoMed. She receives speaker fees from Roche, owns stock in IDbyDNA, and has an ownership interest in CureMatch, Inc. Diviya Gupta has nothing to disclose.
These authors contributed equally to this work.